Patients

SP Sean P. Pitroda
NK Nikolai N. Khodarev
LH Lei Huang
AU Abhineet Uppal
SW Sean C. Wightman
SG Sabha Ganai
NJ Nora Joseph
JP Jason Pitt
MB Miguel Brown
MF Martin Forde
KM Kathy Mangold
LX Lai Xue
CW Christopher Weber
JS Jeremy P. Segal
SK Sabah Kadri
MS Melinda E. Stack
SK Sajid Khan
PP Philip Paty
KK Karen Kaul
JA Jorge Andrade
KW Kevin P. White
MT Mark Talamonti
MP Mitchell C. Posner
SH Samuel Hellman
RW Ralph R. Weichselbaum
request Request a Protocol
ask Ask a question
Favorite

We analyzed samples from 134 adults with liver metastases from primary CRC of which 121 metastases from independent patients successfully underwent molecular analysis (Supplementary Fig. 1). The characteristics of these patients are described in Table 1, Supplementary Data 1, and the Supplementary Methods. We utilized a retrospective clinical cohort study design to identify patients who received uniform treatment for limited (defined as 1–5 lesions involving one or both hepatic lobes), resectable de novo CRC liver metastasis (CRCLM) at two collaborating institutions. We obtained appropriate approval from Institutional Review Boards at each respective cancer center.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A